StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)
StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)
Analysts at StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.
斯托克新闻网的分析师在周一发布给投资者的一份研究报告中开始报道克洛维斯肿瘤公司(纳斯达克代码：CLVS-GET Rating)的股票。该公司对这家生物制药公司的股票设定了“持有”评级。
Separately, JPMorgan Chase & Co. downgraded Clovis Oncology from a "neutral" rating to an "underweight" rating in a research report on Wednesday, November 9th.
另外，摩根大通公司在11月9日星期三的一份研究报告中将Clovis Oncology的评级从中性下调至减持。
Clovis Oncology Stock Down 18.5 %
克洛维斯肿瘤学股票下跌18.5%
CLVS stock opened at $0.08 on Monday. The firm has a market capitalization of $11.60 million, a PE ratio of -0.04 and a beta of 0.24. Clovis Oncology has a twelve month low of $0.08 and a twelve month high of $3.32. The stock has a 50-day simple moving average of $0.62 and a two-hundred day simple moving average of $1.16.
CLVS股票周一开盘报0.08美元。该公司市值为1,160万美元，市盈率为-0.04，贝塔系数为0.24。Clovis Oncology的12个月低点为0.08美元，12个月高位为3.32美元。该股的50日简单移动均线切入位为0.62美元，200日简单移动均线切入位为1.16美元。
Institutional Trading of Clovis Oncology
克洛维斯肿瘤学的机构交易
A number of hedge funds have recently bought and sold shares of CLVS. Vanguard Group Inc. lifted its position in Clovis Oncology by 22.1% in the 1st quarter. Vanguard Group Inc. now owns 12,348,898 shares of the biopharmaceutical company's stock worth $24,945,000 after buying an additional 2,233,797 shares during the last quarter. Millennium Management LLC lifted its position in Clovis Oncology by 49.9% in the 2nd quarter. Millennium Management LLC now owns 5,400,324 shares of the biopharmaceutical company's stock worth $9,721,000 after buying an additional 1,798,313 shares during the last quarter. Renaissance Technologies LLC lifted its position in Clovis Oncology by 139.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,459,900 shares of the biopharmaceutical company's stock worth $2,949,000 after buying an additional 849,500 shares during the last quarter. Palo Alto Investors LP lifted its position in Clovis Oncology by 11.9% in the 1st quarter. Palo Alto Investors LP now owns 4,473,967 shares of the biopharmaceutical company's stock worth $9,037,000 after buying an additional 476,141 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Clovis Oncology by 259.6% in the 3rd quarter. Marshall Wace LLP now owns 310,123 shares of the biopharmaceutical company's stock worth $370,000 after buying an additional 223,880 shares during the last quarter. Institutional investors own 29.47% of the company's stock.
一些对冲基金最近买卖了CLVS的股票。先锋集团在第一季度将其在Clovis Oncology的地位提高了22.1%。先锋集团现在持有这家生物制药公司12,348,898股股票，价值24,945,000美元，在上个季度又购买了2,233,797股。千禧管理公司在第二季度将其在Clovis Oncology的地位提高了49.9%。Millennium Management LLC现在拥有这家生物制药公司5,400,324股股票，价值9,721,000美元，上个季度又购买了1,798,313股。文艺复兴技术公司在第一季度将其在克洛维斯肿瘤学的地位提高了139.2%。复兴科技有限责任公司现在拥有这家生物制药公司1,459,900股票，价值2,949,000美元，在上个季度又购买了849,500股票。Palo Alto Investors LP在第一季度将其在Clovis Oncology的头寸提高了11.9%。Palo Alto Investors LP现在拥有这家生物制药公司4,473,967股票，价值9,037,000美元，上个季度又购买了476,141股票。最后，马歇尔·华斯有限责任公司在第三季度将其在克洛维斯肿瘤学的地位提高了259.6%。马歇尔·华斯有限责任公司现在持有这家生物制药公司310,123股股票，价值37万美元，上个季度又购买了223,880股。机构投资者持有该公司29.47%的股份。
Clovis Oncology Company Profile
Clovis肿瘤学公司简介
(Get Rating)
(获取评级)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology，Inc.是一家生物制药公司，专注于在美国、欧洲和国际上收购、开发抗癌药物并将其商业化。其商业产品包括Rubra(Rucaparib)片剂，这是一种小分子聚ADP-核糖聚合酶抑制剂，用于单一疗法治疗与恶性BRCA突变相关的晚期卵巢癌患者，这些患者已接受两种或两种以上化疗，并由FDA批准的Rubra辅助诊断选择进行治疗。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- How Do Chipmakers Stack Up When It Comes To Growth?
- Is AMC Entertainment Stock Worth Taking Down Here?
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- 免费获取StockNews.com关于克洛维斯肿瘤学(CLVS)的研究报告
- 当谈到增长时，芯片制造商是如何提升的？
- AMC娱乐股票值得在这里下跌吗？
- 是时候去Domino‘s Pizza尝一口了吗？
- MarketBeat：回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引？
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受Clovis肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Clovis Oncology和相关公司的最新新闻和分析师评级的每日简要摘要。